Company: UPC
Filing Date: 2025-03-11
Form Type: 6-K
Source: 0001213900-25-022737
Chunk: 0

Company: Universe Pharmaceuticals INC
Filing Date: 2025-03-11
Form: 6-K
Chunk 0
---
<div align='center'>UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of March 2025

Commission file number: 001-40231

Universe Pharmaceuticals INC

265 Jingjiu Avenue

Jinggangshan Economic and Technological Development Zone

Ji’an, Jiangxi, China 343100

+86-0796-8403309

(Address of principal executive offices)</div>

Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.

<div align='center'>Form 20-F ☒
Form 40-F ☐</div>

Result of the March 2025 Extraordinary General Meeting of Shareholders

On March 8, 2025, Universe Pharmaceuticals INC
(the “Company”) re-convened its extraordinary general meeting of shareholders, originally convened on March 1, 2025 (the “March
2025 Extraordinary General Meeting”) at 10:00 a.m., Beijing Time, at 265 Jingjiu Avenue, Jinggangshan Economy and Technology Development
Zone, Ji’an City, Jiangxi 343100, the People’s Republic of China.

At the March 2025 Extraordinary General Meeting, the
shareholders of the Company adopted resolutions approving both of the two proposals considered at the Meeting. A total of 12.74% of the
8,661,184 votes exercisable as of January 28, 2025, the record date, were present in person or by proxy at the representing less than
one-third (1/3) of the shares carrying the right to vote at the March 2025 Extraordinary General Meeting. However, since the March 2025
Extraordinary General Meeting was adjourned from March 1, 2025 at 10:00 a.m. Beijing Time due to a lack of quorum, and a quorum was not
present at the Meeting within fifteen minutes of the time appointed for the March 2025 Extraordinary General Meeting, the shareholders
present or by proxy shall constitute a quorum in accordance with article 11.2 of the Second Amended and Restated Articles of Association
of the Company